#teva Tech News.
1 story in the last 7 days
The latest teva news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks teva across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
FinanceFinancial Post3 days ago
Teva Closes Emalex Acquisition, Strengthens Neuroscience PipelineTeva closed its acquisition of Emalex Biosciences, adding ecopipam, an investigational drug for pediatric Tourette syndrome. Teva paid $700 million at closing with up to $200 million in potential milestone payments. A U.S. NDA submission for ecopipam is expected in the second half of 2026.
Summaries by ByteBrief